Localized ablative immunotherapy drives de novo CD8+ T-cell responses to poorly immunogenic tumors

Localized ablative immunotherapy drives de novo CD8+ T-cell responses to poorly immunogenic tumors

Background Localized ablative immunotherapies hold great promise in stimulating antitumor immunity to treat metastatic and poorly immunogenic tumors. Tumor ablation is well known to release tumor antigens and danger-associated molecular patterns to stimulate T-cell immunity, but its immune stimulati...

Full description

Bibliographic Details
Main Authors: Mark M Davis, Saghar Kaabinejadian, Abdul Rafeh Naqash, Ashley R Hoover, Jason R Krawic, Xiao-Hong Sun, Qian Yin, Xinbo Yang, K Christopher Garcia, William H Hildebrand, Wei R Chen
Format: Article
Language:English
Published: BMJ Publishing Group 2022-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/10/e004973.full

Internet

https://jitc.bmj.com/content/10/10/e004973.full

Similar Items